Immune implication of FAM83D gene in hepatocellular carcinoma

References

• Maucort-Boulch D, de Martel C, Franceschi S, et al. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide[J]. Int J Cancer. 2018;142(12):2471–2477.
   PubMed Web of Science ®Google Scholar
• Shibata T, Aburatani H. Exploration of liver cancer genomes[J]. Nat Rev Gastroenterol Hepatol. 2014;11(6):340–349.
   PubMed Web of Science ®Google Scholar
• Huo J, Wu L, Development ZY. Validation of a novel immune-gene pairs prognostic model associated with CTNNB1 alteration in hepatocellular carcinoma[J]. Med Sci Monit. 2020;26:e925494.
   PubMed Web of Science ®Google Scholar
• Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma[J]. Cancer Lett. 2020;470:8–17.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Suzuki T, Yoshikawa T, et al. Next-generation cancer immunotherapy targeting glypican-3[J]. Front Oncol. 2019;9:248.
   PubMed Web of Science ®Google Scholar
• Inarrairaegui M, Melero I, Sangro B. Immunotherapy of hepatocellular carcinoma: facts and hopes[J]. Clin Cancer Res. 2018;24(7):1518–1524.
   PubMed Web of Science ®Google Scholar
• Chen B, M S K, C L L, et al. Profiling tumor infiltrating immune cells with CIBERSORT[J]. Methods Mol Biol. 2018;1711:243–259.
   PubMedGoogle Scholar
• Xu H, Xiong C, Chen Y, et al. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma[J]. Bioengineered. 2021;12(1):2664–2675.
   PubMed Web of Science ®Google Scholar
• Cao J, Zhang C, G Q J, et al. Identification of hepatocellular carcinoma-related genes associated with macrophage differentiation based on bioinformatics analyses[J]. Bioengineered. 2021;12(1):296–309.
   PubMed Web of Science ®Google Scholar
• Cipriano R, K L M, B L B, et al. Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer[J]. Mol Cancer Res. 2014;12(8):1156–1165.
   PubMed Web of Science ®Google Scholar
• C A B, Parameswaran N, Cipriano R, et al. FAM83 proteins: fostering new interactions to drive oncogenic signaling and therapeutic resistance[J]. Oncotarget. 2016;7(32):52597–52612.
   PubMedGoogle Scholar
• A M S, S Y L, Hang B, et al. FAM83 family oncogenes are broadly involved in human cancers: an integrative multi-omics approach[J]. Mol Oncol. 2017;11(2):167–179.
   PubMed Web of Science ®Google Scholar
• Liu X, Gao H, Zhang J, et al. FAM83D is associated with gender, AJCC stage, overall survival and disease-free survival in hepatocellular carcinoma[J]. Biosci Rep. 2019;39:5.
   Web of Science ®Google Scholar
• Lin B, Chen T, Zhang Q, et al. FAM83D associates with high tumor recurrence after liver transplantation involving expansion of CD44+ carcinoma stem cells[J]. Oncotarget. 2016;7(47):77495–77507.
   PubMedGoogle Scholar
• M E R, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies[J]. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Ranstam J, Cook JA, Ranstam J, et al. Kaplan-Meier curve[J]. Br J Surg. 2017;104(4):442.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha V, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles[J]. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550.
   PubMed Web of Science ®Google Scholar
• Wang T, Chen B, Meng T, et al. Identification and immunoprofiling of key prognostic genes in the tumor microenvironment of hepatocellular carcinoma[J]. Bioengineered. 2021;12(1):1555–1575.
   PubMed Web of Science ®Google Scholar
• A M N, C L L, M R G, et al. Robust enumeration of cell subsets from tissue expression profiles[J]. Nat Methods. 2015;12(5):453–457.
   PubMed Web of Science ®Google Scholar
• A M N, C L L, M R G, et al. Robust enumeration of cell subsets from tissue expression profiles[J]. Nat Methods. 2015;12(5):453–457.
   PubMed Web of Science ®Google Scholar
• H R A, Chlon L, P D P, et al. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study[J]. PLoS Med. 2016;13(12):e1002194.
   PubMed Web of Science ®Google Scholar
• Ru B, C N W, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions[J]. Bioinformatics. 2019;35(20):4200–4202.
   PubMed Web of Science ®Google Scholar
• Gao J, B A A, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Sci Signal. 2013;6(269):l1.
   Web of Science ®Google Scholar
• H V C, N T D, Szklarczyk D, et al. Viruses.STRING: a virus-host protein-protein interaction database[J]. Viruses. 2018;10:10.
   Web of Science ®Google Scholar
• Herwig R, Hardt C, Lienhard M, et al. Analyzing and interpreting genome data at the network level with ConsensusPathDB[J]. Nat Protoc. 2016;11(10):1889–1907.
   PubMed Web of Science ®Google Scholar
• Zhu J, Liu Y, Ao H, et al. Comprehensive analysis of the immune implication of ACK1 gene in non-small cell lung cancer[J]. Front Oncol. 2020;10:1132.
   PubMed Web of Science ®Google Scholar
• T F G, Mauda-Havakuk M, Heinrich B, et al. Combined locoregional-immunotherapy for liver cancer[J]. J Hepatol. 2019;70(5):999–1007.
   PubMed Web of Science ®Google Scholar
• D F Q, Joyce JA. Microenvironmental regulation of tumor progression and metastasis[J]. Nat Med. 2013;19(11):1423–1437.
   PubMed Web of Science ®Google Scholar
• Schulz M, Salamero-Boix A, Niesel K, et al. Microenvironmental regulation of tumor progression and therapeutic response in brain metastasis[J]. Front Immunol. 2019;10:1713.
   PubMed Web of Science ®Google Scholar
• Asati V, D K M, Bharti SK. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives[J]. Eur J Med Chem. 2016;109:314–341.
   PubMed Web of Science ®Google Scholar
• S M A, S L A, L S S, et al. RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma[J]. Expert Opin Ther Targets. 2019;23(11):915–929.
   PubMedGoogle Scholar
• Xu H, Xiong C, Chen Y, et al. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma[J]. Bioengineered. 2021;12(1):2664–2675.
   PubMed Web of Science ®Google Scholar
• Liu X, Niu X, Qiu Z, et al. Based on stromal/immune scores in the tumor microenvironment and its clinical implications for liver cancer[J]. DNA Cell Biol. 2020;39(9):1621–1638.
   PubMed Web of Science ®Google Scholar
• Ma N, Zhang X, Yu F, et al. Role of IFN-ks, IFN-ks related genes and the DEPDC5 gene in hepatitis B virus-related liver disease[J]. J Viral Hepat. 2014;21(7):e29–e38.
   PubMed Web of Science ®Google Scholar
• Cadoux M, Caruso S, Pham S, et al. Expression of NKG2D ligands is downregulated by beta-catenin signalling and associates with HCC aggressiveness[J]. J Hepatol. 2021;74(6):1386–1397.
   PubMed Web of Science ®Google Scholar
• Yao F, Yuan Q, Song X, et al. Yupingfeng granule improves th2-biased immune state in microenvironment of hepatocellular carcinoma through TSLP-DC-OX40L pathway[J]. Evid Based Complement Alternat Med. 2020;2020:1263053.
   PubMed Web of Science ®Google Scholar
• C N J, Kubes P. Immune surveillance by the liver[J]. Nat Immunol. 2013;14(10):996–1006.
   PubMed Web of Science ®Google Scholar
• Arroyo V, Garcia-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis[J]. J Hepatol. 2014;61(2):396–407.
   PubMed Web of Science ®Google Scholar
• Jia Y, Zeng Z, Li Y, et al. Impaired function of CD4+ T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression[J]. PLoS One. 2015;10(2):e117458.
   Web of Science ®Google Scholar
• Hage C, Hoves S, Strauss L, et al. Sorafenib induces pyroptosis in macrophages and triggers natural killer cell-mediated cytotoxicity against hepatocellular carcinoma[J]. Hepatology. 2019;70(4):1280–1297.
   PubMed Web of Science ®Google Scholar
• Luedde T, Schwabe RF. NF-kappaB in the liver--linking injury, fibrosis and hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol. 2011;8(2):108–118.
   PubMed Web of Science ®Google Scholar
• L M C, Hanson A, J A K, et al. Fam83d modulates MAP kinase and AKT signaling and is induced during neurogenic skeletal muscle atrophy[J]. Cell Signal. 2020;70:109576.
   PubMed Web of Science ®Google Scholar
• Yin C, Lin X, Wang Y, et al. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer[J]. Cell Oncol. 2020;43(3):395–407.
   Web of Science ®Google Scholar
• Ouyang S, Zeng Q, Tang N, et al. Akt-1 and Akt-2 differentially regulate the development of experimental autoimmune encephalomyelitis by controlling proliferation of thymus-derived regulatory T cells[J]. J Immunol. 2019;202(5):1441–1452.
   PubMed Web of Science ®Google Scholar
• Jin F, Wu Z, Hu X, et al. The PI3K/Akt/GSK-3beta/ROS/eIF2B pathway promotes breast cancer growth and metastasis via suppression of NK cell cytotoxicity and tumor cell susceptibility[J]. Cancer Biol Med. 2019;16(1):38–54.
   PubMed Web of Science ®Google Scholar
• Balaji S, Ahmed M, Lorence E, et al. NF-kappaB signaling and its relevance to the treatment of mantle cell lymphoma[J]. J Hematol Oncol. 2018;11(1):83.
   PubMedGoogle Scholar